IDYA (45) TLX (54) ELVN (40) BHC (69) ⌘ Pro Terminal →

Dyne Therapeutics Inc. (DYN) — RQD Stock Rating Cockpit

$17.04 +0.35% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $17.02

Dyne Therapeutics Inc. (DYN) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $3.18B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $17.02 (-0.13%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DYN)Realized 20D OHLCV Swing Band: ±11.9%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY DYN SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (30% of score)

FRED Regime × Technicals: 23% of 52W Range • RSI-14 at 50 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (28% of score)

20D Institutional Volume Accumulation (±11.9% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$16.64-14.4% Next Q

Q2 (-2Q)

Grade E$14.25+9.6% Next Q

Q3 (-1Q)

Grade E$15.62+9.1% Next Q

Current

Grade D-$17.04-7.4% Hist 90D α

Trajectory: E (32) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DYN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DYN currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.53) and Max Pain ($17.89) forces dealer call-delta covering toward $28.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DYN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DYN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

5030 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

1 / 99-Pt Accounting

52-WEEK LASER RANGE23% OF RANGE

L: $14$17.04H: $27

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on DYN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-35.0% ROIC with 42.0% gross margin and -12.73% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (43)

14/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like DYN

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DYN)

✓Walkthrough of DYN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DYN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.91%▲ RESISTANCE BREAKOUT

2026-10-30O $16.97H $17.19L $16.34C $17.04VOL 1.45M

RES: $15.63SUP: $13.96SMA50: $18.53SMA200: $19.31

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DYN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DYN Butterfly Map → + Track DYN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DYN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DYN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DYN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DYN)

Health Care Rank #630 of 1016 ⚔️ IDYA vs DYN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DYN vs. IDYA, TLX, ELVN, BHC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Dyne Therapeutics Inc. (DYN) ranks #630 by composite RQD confidence (40/100, grade D-) and #202 by equity capitalization ($3.18B). Within this direct 5-issuer industry benchmark cohort, BHC leads on earnings valuation at 21.2x trailing P/E, while BHC leads on capital efficiency and profitability with 7.6% ROIC and — gross margin. BHC currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with DYN at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DYN ACTIVE Dyne Therapeutics Inc.	D-	40/100	—	—	-35.0%	+0.35%	$3.18B	Benchmark Subject
IDYA IDEAYA Biosciences Inc.	D	45/100	—	—	-13.8%	-3.15%	$3.17B	/idya-vs-dyn →
TLX Telix Pharmaceuticals Limited	D+	54/100	—	—	—	+2.70%	$3.22B	/tlx-vs-dyn →
ELVN Enliven Therapeutics Inc.	D-	40/100	—	—	-26.2%	+0.67%	$3.30B	/elvn-vs-dyn →
BHC Bausch Health Companies Inc.	C+	69/100	21.2x	—	7.6%	+28.76%	$3.33B	/bhc-vs-dyn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001818794

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dyne Therapeutics Inc. (DYN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$446, operating cash flow of -$403.2M, and free cash flow of -$405.1M (-37.4% YoY). On the balance sheet, DYN closed FY2025 with $1.19B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$446	-$403.2M	-$405.1M	$1.19B	—
FY2024 (FY)	2024-12-31	$0	-$317	-$292.4M	-$294.7M	$691.2M	—
FY2023 (FY)	2023-12-31	$0	-$236	-$188.2M	-$188.2M	—	—

3. DYN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DYN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Dyne Therapeutics Inc. (NASDAQ: DYN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $17.04 (+0.35% 1D, market cap $3.18B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DYN ranks #630 in composite RQD confidence.

How does DYN compare to IDYA and TLX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DYN carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IDYA (IDEAYA Biosciences Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -13.8%, cap $3.17B) and TLX (Telix Pharmaceuticals Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $3.22B). Among the 5-stock peer group, BHC leads on earnings multiple (21.2x) while BHC leads on capital efficiency (7.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DYN?

Per DYN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001818794), Dyne Therapeutics Inc. generated $0 in revenue, -$446 in net income, and -$405.1M in free cash flow against $1.19B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DYN trading relative to its 50-day, 200-day, and 52-week technical levels?

DYN last traded at $17.04 (+0.35% on volume of 1,427,372 shares), positioning the stock -8.04% below its 50-day simple moving average ($18.53) and -11.76% below its 200-day simple moving average ($19.31). Across its 52-week range of $14.00 to $27.31, DYN sits at the 22.8% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.9% ($15.01 to $19.07).

DYN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell DYN stock right now?

Dyne Therapeutics Inc. (DYN) currently earns a Roarable Rating of D- (Sell — SELL) with 40/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is DYN's 12-month price target and RQD AI Jury consensus?

DYN's 12-month base price target is $15.66 (range $12.21 to $28.68), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: DYN RQD Cockpit DYN 12M Forecast DYN Earnings & Move DYN Dividends & DRIP DYN Insiders & 13F DYN Whale Options DYN Profit Sankey DYN News & Why